Article
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer
16 Feb 2019
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.